NEW YORK, NY
SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) (“SUIC”) and VisionRenu Biomedical Technology Co., Ltd. (“VisionRenu”), a Taiwan-based medical technology company specializing in brain health and ophthalmic medical devices, today announced the signing of a Strategic Merger & U.S. Capital Market Cooperation Framework Agreement (MOU).
The framework agreement establishes a long-term strategic partnership to explore collaboration in medical technology, brain health, vision care, healthcare innovation, international financing, and U.S. capital market development.
Under the MOU, the parties intend to evaluate a broad range of strategic opportunities, including:
- Strategic investments;
- Mergers and acquisitions;
- Share exchange transactions
- Business combinations;
- International financing initiatives;
- Product commercialization; and
- U.S. capital market development and expansion.
VisionRenu is the developer of the MagRenu® Transcranial Magnetic Stimulation (TMS) System, a non-invasive, drug-free medical device approved by Taiwan’s Food and Drug Administration (TFDA) for the treatment of depression. The company is also advancing a proprietary ophthalmic technology platform, including an innovative presbyopia laser system designed for international markets.
Through this strategic collaboration, SUIC and VisionRenu expect to leverage their complementary strengths in medical technology innovation, commercialization, international business development, and access to global capital markets. The parties believe the collaboration may accelerate VisionRenu’s international expansion while creating long-term value through strategic financing and potential capital market initiatives in the United States.
Management from both companies expressed confidence that the framework agreement represents an important first step toward building a comprehensive strategic alliance. The parties will continue conducting due diligence and evaluating various transaction structures that may include strategic investment, merger, acquisition, or other forms of business combination, subject to further negotiations, definitive agreements, corporate approvals, and applicable regulatory requirements.
This Framework Agreement is non-binding, except for customary provisions relating to confidentiality and good-faith cooperation, and does not obligate either party to complete any specific transaction.
About VisionRenu Biomedical Technology Co., Ltd.
VisionRenu Biomedical Technology Co., Ltd. is a Taiwan-based medical technology company focused on the research, development, manufacturing, and commercialization of innovative medical devices for brain health and ophthalmic care. Its flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, is approved by Taiwan’s TFDA for the treatment of depression. The company is also developing proprietary ophthalmic laser technologies designed to address the growing global demand for advanced vision care solutions. To learn more about the company, please visit https://www.vision-renu.com/
About SUIC Worldwide Holdings Ltd.
SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) is a technology-enabled investment and business acceleration company focused on acquiring and developing innovative businesses with high-growth potential. Through strategic investments, mergers and acquisitions, and access to international capital markets, SUIC supports portfolio companies in expanding globally and creating long-term shareholder value. Please visit our website, https://sinounitedco.com/
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations regarding future events and are subject to various factors that could cause actual results to differ materially from those expressed or implied. The Framework Agreement announced herein is non-binding, and there can be no assurance that any definitive transaction will be completed. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
Media Contact
SUIC Worldwide Holdings Ltd.
News Release Department (929) 391-2550.
Name
Jenny Kan
Email Address